Indpendent Voices Day Support Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 154 Newtown Rd, Suite B2-100, Va Beach, VA 23462 Phone: 757-729-0480 |
Futures Counseling Corporation Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 900 Commonwealth Pl Ste 200, Va Beach, VA 23464 Phone: 757-353-9616 Fax: 757-313-6634 |
Ict Services, Inc. Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 6465 College Park Sq Ste 300, Va Beach, VA 23464 Phone: 757-351-0057 Fax: 757-351-6890 |
News Archive
The implant, manufactured by Santa Barbara-based Sientra, can be used for breast tissue reconstruction for women of any age and for breast augmentation in women 22 or older. The approval resulted from three years of clinical studies on almost 1,800 patients. Tightening of the area around the implant, re-operation, implant removal, uneven appearance and infection were some of the complications experienced during the study. Sientra is required to continue studies on the implant's long-term safety, effectiveness and risks of rare diseases under the approval.
The University of Michigan's first human embryonic stem cell line will be placed on the U.S. National Institutes of Health's registry, making the cells available for federally-funded research. It is the first of the stem cell lines derived at the University of Michigan to be placed on the registry.
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular Research and of Heidelberg University Hospital have obtained new findings which indicate that a previously undetected signal pathway causes or protects from heart failure - depending on the type of stress.
Researchers at Moffitt Cancer Center and colleagues analyzed national data to investigate the differences in cancer prevention beliefs by race and ethnicity. They found that minorities, including blacks, Asians and Hispanics, have differing beliefs about cancer prevention and feel they are less likely to get cancer than did whites.
Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.
› Verified 8 days ago